Key result
Novel pharmacological interventions and their potential mechanisms of action for maintaining sinus rhythm after direct current cardioversion in atrial fibrillation are reviewed.
Why the study?
Do novel adjunctive pharmacological therapies improve the maintenance of sinus rhythm after direct current cardioversion in patients with atrial fibrillation?
Do novel adjunctive pharmacological therapies improve the maintenance of sinus rhythm after direct current cardioversion in patients with atrial fibrillation?
This review highlights emerging adjunctive pharmacological therapies that may help maintain sinus rhythm following direct current cardioversion for atrial fibrillation.
Emerging agents may aid post-cardioversion rhythm control in AF; leaves open confirmation in randomized trials before practice change.
Despite the availability of potentially curative interventions for atrial fibrillation, there remains an important role for conventional anti-arrhythmic therapy and anti-coagulation combined with direct current cardioversion. Unfortunately, the latter approach is disturbed by high recurrence rates of atrial fibrillation. In recent years, several adjunctive therapies have emerged which may facilitate the maintenance of sinus rhythm. These novel therapies and their potential mechanisms of action are reviewed in this article.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2011) conducted a review in Atrial fibrillation. Novel pharmacological interventions was evaluated. Novel pharmacological interventions and their potential mechanisms of action for maintaining sinus rhythm after direct current cardioversion in atrial fibrillation are reviewed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: